Publication Name	World Journal of Immunology
Manuscript ID	10368
Country	India

Received	2014-03-28 10:45
Peer-Review Started	2014-03-31 10:34
To Make the First Decision	2014-04-28 14:33
Return for Revision	2014-04-30 16:02
Revised	2014-05-10 22:07
Second Decision	2014-06-27 17:39
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-06-27 17:53
Articles in Press	2014-06-27 18:13
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-07-21 15:15
Publish the Manuscript Online	2014-07-27 18:55

ISSN	2219-2824 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Immunology
Manuscript Type	Review
Article Title	Targeting TLR4/MAPKs signaling pathway: A better option for therapeutic inhibition of atherosclerosis
Manuscript Source	Invited Manuscript
All Author List	Janeesh Plakkal Ayyappan and Annie Abraham
Funding Agency and Grant Number	Funding Agency Grant Number University of Kerala, India for the study
Corresponding Author	Dr. Annie Abraham, Director, Professor of Biochemistry, Department of Biochemistry, School of Life sciences, University of Kerala, Palayam Airport Road, Kariavattom Campus 695 581, India. annieab2001@gmail.com
Key Words	Atherosclerosis; Toll-like receptor 4; Mitogen activated protein kinase; Foam cells; Inflammatory markers
Core Tip	The inhibition of atherosclerosis is one of primary target for the therapeutics of cardiovascular diseases, which is the eminent health problem worldwide. The important function of toll-like receptor 4 (TLR4) in the activation and progression of atherosclerosis is justified here. The TLR4 in turn activates the mitogen activated protein kinase (MAPKs) and nuclear factor kappa-light-chain-enhancer of activated B cells which are responsible for most of the inflammatory events. Hence, therapeutic inhibition of TLR4/MAPKS signaling pathway is one of the best method of inhibiting atherosclerosis.
Publish Date	2014-07-27 18:55
Citation	Plakkal Ayyappan J, Abraham A. Targeting TLR4/MAPKs signaling pathway: A better option for therapeutic inhibition of atherosclerosis. World J Immunol 2014; 4(2): 116-121
URL	http://www.wjgnet.com/2219-2824/full/v4/i2/116.htm
DOI	http://dx.doi.org/10.5411/wji.v4.i2.116

Full Article (PDF)	WJI-4-116.pdf
Full Article (Word)	WJI-4-116.doc
Manuscript File	10368-Review.doc
Answering Reviewers	10368-Answering reviewers.pdf
Copyright License Agreement	10368-Copyright assignment.pdf
Peer-review Report	10368-Peer review(s).pdf
Scientific Misconduct Check	10368-CrossCheck.jpg
Scientific Editor Work List	10368-Scientific editor work list.pdf